GlassScriptPhysician profile
Vagisha Sharma
NPI 1972543429
$9,349.06
in general payments reported to CMS, 2019-2025
31 companies · $6,148 in 2025
The $6,148 reported for 2025 was more than what 98% of Obstetrics providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $200 · 2020: $55.03 · 2021: $431 · 2022: $369 · 2023: $173 · 2024: $1,974 · 2025: $6,148.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $7,800 · Food and Beverage: $495.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $7,800.00 |
| Food and Beverage | $494.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mimedx Group, INC. | $7,800.00 | 2024-2025 | Bovine Collagen |
| Abbvie INC. | $263.51 | 2021-2023 | Lo Loestrin Fe, Liletta |
| Exeltis, USA INC. | $212.64 | 2019-2025 | Slynd |
| Mayne Pharma Commercial LLC | $145.06 | 2021-2025 | |
| Pfizer INC. | $96.68 | 2021-2024 | |
| Vertical Pharmaceuticals, LLC | $84.51 | 2019 | |
| Organon LLC | $69.52 | 2021-2024 | Nexplanon |
| Merck Sharp & Dohme LLC | $57.81 | 2020-2021 | |
| Astellas Pharma US INC | $49.50 | 2023-2024 | Veozah |
| Myovant Sciences INC. | $47.10 | 2021 | |
| Virtus Pharmaceuticals LLC | $43.55 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $40.45 | 2021-2023 | |
| Agile Therapeutics, INC. | $36.78 | 2021-2023 | Twirla |
| Coopersurgical, INC. | $34.02 | 2025 | Ally II Ups |
| Mission Pharmacal Company | $33.50 | 2021-2024 | Citranatal Medley |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Therapeuticsmd, INC. | $30.96 | 2021-2022 | |
| Davol INC. | $28.54 | 2025 | Arista |
| Channel Medsystems, INC. | $27.57 | 2022 | |
| Sage Therapeutics, LLC | $25.59 | 2025 | Zurzuvae |
| Minerva Surgical, INC | $23.98 | 2021 | |
| Mycovia Pharmaceuticals, INC. | $23.28 | 2023 | Vivjoa |
| Ethicon US, LLC | $23.21 | 2025 | Vistaseal, Surgicel Nu-Knit, Stratafix |
| Mylan Pharmaceuticals INC. | $22.78 | 2022 | |
| Aspira Women'S Health INC | $21.53 | 2019 | |
| Amag Pharmaceuticals, INC. | $19.26 | 2021 | |
| Hologic Sales and Service, LLC | $17.97 | 2022 | |
| Lupin INC. | $15.83 | 2019 | |
| Avion Pharmaceuticals | $15.36 | 2019 | |
| Smith+Nephew, INC. | $14.63 | 2024 | Pico 14 |
| Eisai INC. | $12.14 | 2021 | |
| Duchesnay USA Incorporated | $11.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vagisha Sharma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.